GSK picks up pulmonary hypertension drug with 35Pharma acquisition

LONDON — Building up its base of medicines for lung diseases, GSK said Wednesday it was buying the privately held firm 35Pharma for $950 million in cash.

The centerpiece of the deal is an experimental drug called HS235 that is set to start trials in pulmonary arterial hypertension, a form of high blood pressure in the lungs. 

The disease has increasingly become a target for drugmakers in recent years. Merck’s Winrevair won approval for PAH in 2024, and reached $1.4 billion in sales last year. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In